Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4640095 | 1.00 | ADRB3 (0.73) | ADRB3ADRB1 | |
| SCHEMBL1593308 | 0.95 | ADRB3 (0.71) | ADRB3ADRB1 | |
| SCHEMBL1593313 | 0.95 | ADRB3 (0.71) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL1592823 | 0.93 | ADRB3 (0.69) | ADRB3ADRB1 | |
| SCHEMBL9513722 | 0.91 | ADRB3 (0.69) | ADRB3ADRB1 | |
| Hydrochloric Acid SCHEMBL9306877 | 0.91 | ADRB3 (0.68) | ADRB3ADRB1 | |
| Oxalic Acid SCHEMBL8765797 | 0.88 | ADRB3 (0.69) | ADRB3ADRB1 | |
| SCHEMBL9006697 | 0.86 | ADRB3 (0.67) | ADRB3ADRB1 | |
| SCHEMBL16666148 | 0.86 | ADRB3 (0.80) | ADRB3ADRB1 | |
| SCHEMBL3881745 | 0.86 | ADRB3 (0.73) | ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0858325-B1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI SYNTHELABO (FR) | 2002-07-31 | — | — | EP | claimed |
| US-9145451-B2 | Glucagon superfamily peptides exhbiting G protein coupled receptor activity | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-09-29 | — | — | US | disclosed |
| US-20130116172-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY | MARCADIA BIOTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| EP-0858325-B1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI SYNTHELABO (FR) | 2002-07-31 | — | — | EP | disclosed |
| EP-0858325-A1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI (FR) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997017064-A1 | STABLE FREEZE-DRIED PHARMACEUTICAL FORMULATION | SANOFI (FR) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116172-A1 | GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY | GCGR, GLP1R, GIPR | ADRB3 186/4885ADRB1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.